Premedication and chemotherapy agents do not impair imgatuzumab (GA201)-Mediated antibody-dependent cellular cytotoxicity and combination therapies enhance efficacy

Clinical Cancer Research

Volumn 22, Issue 10, 2016, Pages 2453-2461

  Gonzalez Nicolini, Valeria ^a   Herter, Sylvia ^a   Lang, Sabine ^a   Waldhauer, Inja ^a   Bacac, Marina ^a   Roemmele, Michaela ^a   Bommer, Esther ^a   Freytag, Olivier ^a   Van Puijenbroek, Erwin ^a   Umãna, Pablo ^a   Gerdes, Christian A ^a  

^a Roche Innovation Center Zurich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOXYCYCLINE; FIRTECAN; FOLIC ACID; GEMCITABINE; GRANISETRON; HYDROCORTISONE; IMGATUZUMAB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANTOPRAZOLE; PREDNISOLONE; RANITIDINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; COLORECTAL LIVER METASTASIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LUNG CANCER; MOUSE; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREMEDICATION; PRIORITY JOURNAL; TUMOR XENOGRAFT; A-549 CELL LINE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HT-29 CELL LINE; METABOLISM; MONONUCLEAR CELL; MULTIMODALITY CANCER THERAPY; PROCEDURES; TUMOR CELL LINE;

A549 CELLS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CETUXIMAB; COMBINED MODALITY THERAPY; HT29 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84968884507     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2579     Document Type: Article

References (36)

1. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6.
2. Schweiger T, Hegedus B, Nikolowsky C, Hegedus Z, Szirtes I, Mair R, et al. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann Surg Oncol 2014;21:946-54.
3. Gerdes CA, Nicolini V, Herter S, van Puijenbroek E, Lang S, Roemmele M, et al. GA201 (RG7160): a novel, humanised, glycoengineered anti-EGFR antibody with enhancedADCC andsuperiorin vivo efficacy compared with cetuximab. Clin Cancer Res 2013;19:1126-38.
4. Paz Ares L, Gomez Roca C, Delord JP, Cervantes A, Markman B, Corral J, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor (EGFR) in patients with advanced solid tumors. J Clin Oncol 2011;29:3783-90.
5. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9.
6. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008;13:725-32.
7. Song X, Long SR, Barber B, Kassed CA, Healey M, Jones C, et al. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012;7:56-65.
8. Merck KGaA. Erbitux®summary of product characteristics. Darmstadt, Germany; 2012.
9. Roche Registration Ltd. MabThera® summary of product characteristics. Welwyn Garden City, United Kingdom; 2012.
10. Genzyme Europe BV. MabCampath ®Summary of product characteristics. Naarden, the Netherlands; 2012.
11. Janssen Biologics BV. Remicade® summary of product characteristics. Leiden, the Netherlands; 2012.
12. Sumikawa T, Shigeoka Y, Igishi T, Suyama H, Yamasaki A, Hashimoto K, et al. Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int J Oncol 2008;32:683-8.
13. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002;100: 1765-73.
14. Dienstmann R, Markman B, Tabernero J. Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol 2012; 7:137-45.
15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
16. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8.
17. Lenz HJ, Van CE, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
18. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
19. Wierzbicki R, Jonker DJ, Moore MJ, Berry SR, Loehrer PJ, Youssoufian H, et al. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 2011;29:167-74.
20. Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYS-TAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75.
21. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
22. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48.
23. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6: 4874-84.
24. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
25. Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci 2009;38:283-90.
26. Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007;6:644-54.
27. Markasz L, Skribek H, Uhlin M, Otvos R, Flaberg E, Eksborg S, et al. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 2008;31:283-93.
28. Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, et al. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. Eur J Cancer 2014;50:496-505.
29. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9.
30. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008;26:5335-43.
31. Buzaid AC, Mathias CC, Perazzo F, Simon SD, Fein L, Hidalgo J, et al. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer 2010;9: 282-9.
32. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
33. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-27.
34. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated cytotoxicity (ADCC). Eur J Cancer 2010;46:1703-11.
35. Ekblad L, Johnsson A. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. Anticancer Res 2012;32:783-6.
36. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005;16 Suppl 4:iv61-8.